Elafibrinor approved by MHRA for treatment of adult patients in the UK
February 06, 2025 • Estimated Reading Time: 1 minute
Latest Research
Recent FDA actions concerning obeticholic acid, a medication for primary biliary cholangitis (PBC), have prompted healthcare professionals to reassess its long-term safety. As a result, there's a growing need to support patients transitioning to other treatments. This situation is complicated by the challenges of securing insurance coverage for newer PBC therapies. Pharmacy times (2025) highlights the importance of developing strategies to navigate these access issues effectively.
Healthcare teams are now tasked with finding ways to ensure patients can access and afford these new treatment options. The article underscores the necessity for a collaborative approach among healthcare providers, patients, and insurance companies to manage PBC effectively in light of the evolving therapeutic landscape.
More Info 
Add to Calendar